Multicentric EORTC retrospective study shows efficacy of Brentuximab Vedotin in Μycosis Fungoides and Sezary Syndrome patients with variable CD30 positivity.
Brentuximab Vedotin (BV) was approved as therapy for Mycosis Fungoides (MF) based on ALCANZA trial. Since then few real-life data are available.The aim of this study was to evaluate efficacy and safety of BV in MF/Sezary Syndrome (SS) patients with variable CD30 positivity in real life cohort and explore potential predictors.Data from 72 MF/SS patients across 9 EORTC (European Organization for Research and Treatment of Cancer) centers were included. The primary endpoint was to evaluate the proportion of patients with: overall response (ORR), ORR lasting over four months (ORR4), time to response (TTR), response duration (RD), progression free survival (PFS) and time to next treatment (TTNT). Secondary aims included safety evaluation and association of clinicopathological features with ORR, RD and TTNT.Seventy-two patients were included; all had received at least one systemic treatment. ORR was achieved in 45/67; ORR4 in 28/67 with median TTR 8 weeks (IQR 5.5-14) and median RD 9 months (IQR 3.4-14). Median PFS was 7 months (IQR 2-12) and median TTNT 30 days (6-157.5). Patients’ response, RD, PFS and TTNT were not associated with any clinicopathological characteristics. In MF group, patients with stage IIB/III versus IV achieved longer PFS and higher percentage of ORR4. There was statistically significant association between LCT and skin ORR (p=0.03). ORR4 was more frequently achieved in patients without lymph node involvement (p=0.04).BV is an effective option for MF/SS patients including those with variable CD30 positivity, LCT, SS, longer disease duration and highly pretreated.
Authors: E Papadavid, E Kapniari, V Pappa, V Nikolaou, T Iliakis, M Dalamaga, C Jonak, S Porkert, S Engelina, P Quaglino, P L Ortiz-Romero, C Vico, A Cozzio, F Dimitriou, R Guiron, E Guenova, E Hodak, M Bagot, J Scarisbrick